- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:34 | OKYO Pharma to Present at OIS XV in San Diego | 98 | GlobeNewswire (Europe) | LONDON and NEW YORK, Nov. 18, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 13:30 | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 29.10. | OKYO Pharma to Present at BIO-Europe 2025 in Vienna | 242 | GlobeNewswire (Europe) | LONDON and NEW YORK, Oct. 29, 2025), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA... ► Artikel lesen | |
| 29.10. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 16.10. | Insider-Kauf bei OKYO Pharma: Gesellschaft des Executive Chairman erwirbt 210.000 Aktien an der NASDAQ | 3 | Investing.com Deutsch | ||
| 16.10. | OKYO Pharma Announces Chairman and Founder Acquires Shares | 218 | GlobeNewswire (Europe) | LONDON and NEW YORK, Oct. 16, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
| 16.10. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 23.09. | OKYO Pharma: H.C. Wainwright bestätigt Kaufempfehlung nach Ankündigung neuer klinischer Studie | 2 | Investing.com Deutsch | ||
| 23.09. | OKYO Pharma stock maintains Buy rating at H.C. Wainwright on clinical trial plans | 1 | Investing.com | ||
| 22.09. | OKYO Pharma advances urcosimod to next clinical trial for eye pain | 4 | Investing.com | ||
| 22.09. | OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain | 202 | GlobeNewswire (Europe) | LONDON and NEW YORK, Sept. 22, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 22.09. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 18.07. | OKYO Pharma Ltd - 20-F, Annual and transition report of foreign private issuers | 4 | SEC Filings | ||
| 17.07. | OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain | 346 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 17, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 17.07. | OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data | 2 | Investing.com | ||
| 16.07. | OKYO Pharma Stock Rises 8% On Positive Phase 2 Trial Results For Neuropathic Corneal Pain Therapy | 3 | RTTNews | ||
| 16.07. | OKYO Pharma reports results from Urcosimod trial | 2 | Seeking Alpha | ||
| 16.07. | OKYO Pharma meldet positive Top-Line-Ergebnisse aus Phase-2-Studie mit Urcosimod | - | Investing.com Deutsch | ||
| 16.07. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 16.07. | OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain | 212 | GlobeNewswire (Europe) | After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating... ► Artikel lesen |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IDEXX LABORATORIES | 572,20 | -0,87 % | Stifel reiterates Buy rating on IDEXX Laboratories stock, maintains $775 price target | ||
| BIOXCEL THERAPEUTICS | 1,568 | -1,26 % | BioXcel Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| ADAPTIMMUNE THERAPEUTICS | 0,035 | +1,47 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,470 | -2,25 % | Voyager Therapeutics stock price target lowered to $25 at H.C. Wainwright | ||
| ANAVEX LIFE SCIENCES | 3,091 | +0,52 % | Anavex Life Sciences Corp.: Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease | Company plans to request re-examination after CHMP opinion feedback following its oral explanation FDA advises Company to meet and discuss Company's Alzheimer's Disease clinical trial results NEW... ► Artikel lesen | |
| CELLAVISION | 14,140 | -1,26 % | CellaVision: Softer Quarter with Mixed Regional Performance | Organic sales growth:Q3, 2025: 2.6% (9.4)EBITDA margin:Q3, 2025: 28% (27)July 1st - September 30th, 2025Net sales decreased by -1.7% (6.4) to SEK 176 m (179).Sales increased organically by 2.6% (9.4)... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 4,920 | +11,82 % | Precision BioSciences launches $75M stock and warrant offering | ||
| ZYMEWORKS | 20,200 | -2,88 % | Zymeworks Inc.: Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer | VANCOUVER, British Columbia, Nov. 18, 2025(Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics... ► Artikel lesen | |
| VTV THERAPEUTICS | 26,000 | 0,00 % | vTv Therapeutics Inc.: vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced... ► Artikel lesen | |
| QUOIN PHARMACEUTICALS | 13,700 | +2,24 % | Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies | Target Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 4,750 | 0,00 % | Neuphoria Therapeutics, Inc.: Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value | Confirms Receipt of Unsolicited Indication of Interest and Director Nominations from Lynx1 Master Fund LP No Stockholder Action Required at This Time BURLINGTON, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| NUVATION BIO | 4,665 | 0,00 % | Nuvation Bio Inc. (NUVB) is a Buy at H.C. Wainwright on Cancer Drug Development Progress | ||
| MIRA PHARMACEUTICALS | 1,200 | +1,69 % | MIRA PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | ||
| PLIANT THERAPEUTICS | 1,500 | +5,63 % | Pliant Therapeutics, Inc.: Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results | Oncology program advancing with data expected in the fourth quarter 2025 BEACON-IPF close out activities to be completed in the fourth quarter 2025 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE... ► Artikel lesen | |
| ONCONETIX | 2,200 | -1,79 % | Onconetix, Inc. - 10-Q, Quarterly Report |
OKYO PHARMA LIMITED gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,150 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OKYO PHARMA LIMITED finden Sie auf Wallstreet Online.